Q3 EPS Forecast for Atara Biotherapeutics Lifted by Analyst

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) – Research analysts at HC Wainwright increased their Q3 2025 earnings estimates for shares of Atara Biotherapeutics in a research note issued to investors on Tuesday, January 28th. HC Wainwright analyst R. Burns now expects that the biotechnology company will earn $3.57 per share for the quarter, up from their previous forecast of $3.35. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Atara Biotherapeutics’ current full-year earnings is ($9.86) per share.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The business had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same period in the previous year, the company posted ($16.50) earnings per share.

Other research analysts have also issued research reports about the company. Rodman & Renshaw began coverage on Atara Biotherapeutics in a report on Friday, December 20th. They issued a “buy” rating and a $25.00 target price on the stock. Canaccord Genuity Group cut their price objective on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, January 17th. RODMAN&RENSHAW cut shares of Atara Biotherapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 21st. Finally, TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. One analyst has rated the stock with a sell rating, three have given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.75.

Atara Biotherapeutics Stock Down 3.2 %

ATRA opened at $8.09 on Wednesday. Atara Biotherapeutics has a 52 week low of $5.40 and a 52 week high of $39.50. The business has a 50 day moving average price of $11.78 and a two-hundred day moving average price of $9.93. The company has a market cap of $46.60 million, a PE ratio of -0.31 and a beta of 0.51.

Hedge Funds Weigh In On Atara Biotherapeutics

Large investors have recently made changes to their positions in the stock. Vestal Point Capital LP increased its position in shares of Atara Biotherapeutics by 11.3% in the third quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock valued at $1,014,000 after buying an additional 12,677 shares in the last quarter. Cubist Systematic Strategies LLC acquired a new stake in Atara Biotherapeutics in the 2nd quarter valued at about $79,000. State Street Corp increased its holdings in Atara Biotherapeutics by 52.3% during the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares in the last quarter. FMR LLC increased its holdings in Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after acquiring an additional 7,381 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Atara Biotherapeutics during the second quarter worth about $53,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.